Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

GSK plc (NYSE:GSK) develops and markets a wide range of healthcare products, including vaccines, specialty medicines, and ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

In this article, in addition to analyzing GSK's financial results for Q4 2024, I also presented an analysis of the most interesting developments in its portfolio. However, that's not all.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.